GlassScriptPhysician profile
Robert S Golden
NPI 1992887541
$1,813.59
in general payments reported to CMS, 2019-2025
17 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2022: $196 · 2023: $638 · 2024: $425 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.91 | 2019-2025 | |
| Novo Nordisk INC | $407.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $318.12 | 2019-2025 | |
| Amgen INC. | $136.75 | 2019-2024 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $111.07 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $94.06 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.01 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $49.21 | 2023 | Cologuard Collection Kit |
| Supreme Orthopedic Systems, LLC | $41.99 | 2023 | |
| Idorsia Pharmaceuticals US INC | $28.95 | 2023 | Quviviq |
| Lilly USA, LLC | $26.72 | 2024-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $24.27 | 2023 | Xarelto |
| Hologic Sales and Service, LLC | $24.11 | 2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.92 | 2025 | Xifaxan |
| Medtronic USA, INC. | $19.78 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $18.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.